Answers are grounded in this paper and cite their sources.
Cancer stem-like cells (CSCs) have been implicated in tumor recurrence, therapeutic resistance, and metastatic progression, making their metabolic dependencies potential therapeutic targets. We investigated oxidative phosphorylation (OXPHOS) as a metabolic vulnerability of triple-negative breast cancer (TNBC) stem-like cells and evaluated the effects of mitochondrial metabolic intervention in vitro and in vivo. Mammosphere-derived cells exhibited enhanced mitochondrial respiration. Building on our previous findings that the repurposed antimicrobials amoxicillin (AMX) and fosmidomycin sodium salt (FSS) inhibit OXPHOS, we now demonstrate that these agents also suppress mammosphere formation, reduce mitochondrial respiratory activity, and increase oxidative stress and mitophagy in CSC-like TNBC cells. In vivo, mammosphere-derived cells exhibited increased metastatic potential, as indicated by greater lymph-node enlargement and lung nodule burden, which were significantly reduced by AMX treatment. In a complementary tumor-establishment model, administration of AMX for approximately two weeks before cell implantation delayed subsequent tumor development. These findings indicate that targeting mitochondrial metabolism can impair tumor establishment and reduce metastatic-associated outcomes in a TNBC stem-like cell model. Cancer stem cells, resistance, metastatic potential, OXPHOS, mitochondria, chemoprevention
No takes yet. Share an insight, caveat, or question.
Uslu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: